ClinicalTrials.gg
CompletedNCT01466153Updated May 31, 2017Results posted

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of Rituximab and Bendamustine in Chronic Lymphocytic Leukemia (CLL), sponsored by MedImmune LLC. Completed at 54 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-05-31.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca — 6 open to participants now, 21 under way, 5 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AstraZeneca.

Enrollment
10th of 29
183 · median 103
Started
2012
the only one that year
Phase 2
5 of 42
1 open now
Registered
6th of 42
by date

Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 10th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2012, is one of 5 in phase 2, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

6 of the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)

Keywords

  • Chronic lymphocytic leukemia; leukemia; B-Cell malignancy; anti-CD19; monoclonal antibody; CLL; Refractory; Relapse; Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed B-cell Chronic Lymphocytic Leukemia (CLL) according to the National Cancer Institute criteria; (ECOG) performance status of 0, 1, or 2; Adequate hematological function

Exclusion criteria

Exclusion Criteria:

  • Any chemotherapy, radiotherapy, immunotherapy, biologic, , or hormonal therapy for treatment of lymphoma within 28 days prior to treatment;
  • Exposure to bendamustine within the 180 days before study enrollment
  • Prior or allogeneic stem cell transplantation (SCT);
  • abnormality on (ECG) as determined by the treating physician or medical monitor;
  • History of other invasive within 5 years except for localized/in situ carcinomas;
  • Evidence of active infection, Confirmed current central nervous system involvement by leukemia or lymphoma;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
183 participants (actual)

Study arms

  • Active comparator
    Rituximab + Bendamustine

    Rituximab was administered by IV infusion as 375 mg/m\^2 on Day 2 of Cycle 1 and then 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.

    Drug: Rituximab · Drug: Bendamustine

  • Experimental
    MEDI-551 2 mg/kg + Bendamustine

    MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.

    Drug: Bendamustine · Drug: MEDI-551

  • Experimental
    MEDI-551 4 mg/kg + Bendamustine

    MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.

    Drug: Bendamustine · Drug: MEDI-551

Interventions

  • Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles

    Also known as: Rituxan; MabThera

  • Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.

  • MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    ORR, defined as the proportion of participants with complete response (CR) or partial response (PR) out of total number of participants. Responses were assessed by using National Cancer Institute - Working Group guidelines on CLL.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)

    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug (MEDI-551). A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and Day 90 that were absent before treatment or that worsened relative to pre-treatment state. An AESIs was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through Day 90 after the last dose of study drug.Hepatic function abnormality and infusion reactions resulting in discontinuation were considered as AESIs.

    Time frame: From time of consent to 90 days post last dose

  2. Number of Participants With Abnormal Clinical Laboratory Parameters Reported as AEs

    An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.

    Time frame: From time of consent to 90 days post last dose

  3. Number of Participants With Abnormal Vital Signs and Electrocardiogram Reported as AEs

    AEs observed in participants with clinically significant ECG abnormalities were assessed.

    Time frame: From time of consent to 90 days post last dose

  4. Complete Response Rate

    Complete response was as per IWG was the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  5. Minimal Residual Disease Negative Complete Response (CR) Rate

    The MRD-negative CR rate was defined as the percentage of participants who achieved CR and became MRD-negative as determined by flow cytometry. CR as per International Working Group (IWG) was complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  6. Time to Response

    Time to response was evaluated using the Kaplan-Meier method.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  7. Time to Disease Progression (TTP)

    TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  8. Progression Free Survival (PFS)

    PFS was measured from the start of treatment with study drug until the first documentation of disease progression or death due to any cause, whichever occurred first. Kaplan-Meier method was used for evaluation.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  9. Overall Survival (OS)

    OS was determined as the time from the start of treatment with study drug until death due to any cause. For participants who were alive at the end of the study or lost to follow-up, OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  10. Number of Participants Who Developed Detectable Anti-drug Antibodies (ADA)

    A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.

    Time frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)

  11. Terminal Half Life (t1/2) of MEDI-551

    Terminal phase elimination half-life (T1/2) was the time required for half of the drug to be eliminated from the serum.

    Time frame: Pre-infusion and 1 hour post infusion on Days 2 and 8, Days 15 and 22 of cycle 1

07

Results

Posted May 31, 2017

Participant flow

Participant flow — Overall Study
MilestoneRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Started623661
Completed331236
Not completed292425
Withdrew: Disease progression220
Withdrew: Adverse event141317
Withdrew: Withdrawal of consent200
Withdrew: Investigator discretion322
Withdrew: Randomized-not treated234
Withdrew: Other-unspecified642

Outcome measures

PrimaryObjective Response Rate

ORR, defined as the proportion of participants with complete response (CR) or partial response (PR) out of total number of participants. Responses were assessed by using National Cancer Institute - Working Group guidelines on CLL.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Objective Response Rate59.7 (46.4 to 71.9)52.8 (35.5 to 69.6)63.9 (50.6 to 75.8)
Statistical analysis
  • Rituximab + Bendamustine vs MEDI-551 4 mg/kg + Bendamustine · Cochran-Mantel-Haenszel · p = 0.4475
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug (MEDI-551). A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and Day 90 that were absent before treatment or that worsened relative to pre-treatment state. An AESIs was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through Day 90 after the last dose of study drug.Hepatic function abnormality and infusion reactions resulting in discontinuation were considered as AESIs.

Time frame:
From time of consent to 90 days post last dose
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
TEAEs583357
TESAEs191619
AESIs246
SecondaryNumber of Participants With Abnormal Clinical Laboratory Parameters Reported as AEs

An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.

Time frame:
From time of consent to 90 days post last dose
Reported as:
Number · Participants
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as AEs
ParticipantsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Hyperbilirubinaemia021
Hypercalcaemia100
Hypercholesterolaemia101
Hyperglycaemia421
Hyperkalaemia212
Hyperlipidaemia010
Hypermagnesaemia100
Hyperphosphataemia011
Hypertriglyceridaemia100
Hyperuricaemia352
Hypoalbuminaemia202
Hypocalcaemia311
Hypokalaemia614
Hypomagnesaemia221
Hyponatraemia210
Alanine Aminotransferase Increased103
Aspartate Aminotransferase Increased103
Blood Alkaline Phosphatase Increased112
Blood Bilirubin Increased011
Blood Cholesterol Decreased001
Blood Creatinine Decreased100
Blood Creatinine Increased121
Blood Immunoglobulin G Decreased001
Blood Lactate Dehydrogenase Increased400
Blood Urea Increased110
Gamma-Glutamyltransferase Increased112
Hepatic enzyme Increased100
Anaemia1879
Eosinophilia001
Lymphopenia431
Neutropenia281019
Thromobocytopenia12610
Activated Partial Thromboplastin Time Prolonged200
Blood Fibrinogen Increased100
Blood Immunoglobulin g Decreased001
Haemoglobin Decreased010
Lymphocyte Count Decreased302
Neutrophil Count Decreased913
Platelet Count Decreased223
Prothrombin Time Shortened100
Haematuria021
Proteinuria010
White Blood Cells in Urine001
SecondaryNumber of Participants With Abnormal Vital Signs and Electrocardiogram Reported as AEs

AEs observed in participants with clinically significant ECG abnormalities were assessed.

Time frame:
From time of consent to 90 days post last dose
Reported as:
Number · Participants
Number of Participants With Abnormal Vital Signs and Electrocardiogram Reported as AEs
ParticipantsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Atrial Fibrillation121
Atrioventricular Block100
Palpitations002
Sinus Bradycardia100
Sinus Tachycardia100
Tachycardia211
Pyrexia201114
Dyspnoea924
Dyspnoea Exertional310
Hypertension101
Hypotension526
Orthostatic Hypotension001
SecondaryComplete Response Rate

Complete response was as per IWG was the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Number · Percentage of Participants
Complete Response Rate
Percentage of ParticipantsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Complete Response Rate6.5 (1.8 to 15.7)5.6 (0.7 to 18.7)11.5 (4.7 to 22.2)
Statistical analysis
  • Rituximab + Bendamustine vs MEDI-551 4 mg/kg + Bendamustine · Cochran-Mantel-Haenszel · p = 0.3206
SecondaryMinimal Residual Disease Negative Complete Response (CR) Rate

The MRD-negative CR rate was defined as the percentage of participants who achieved CR and became MRD-negative as determined by flow cytometry. CR as per International Working Group (IWG) was complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Number · Percentage of Participants
Minimal Residual Disease Negative Complete Response (CR) Rate
Percentage of ParticipantsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Minimal Residual Disease Negative Complete Response (CR) Rate1.6 (0.0 to 8.7)5.6 (0.7 to 18.7)4.9 (1.0 to 13.7)
Statistical analysis
  • Rituximab + Bendamustine vs MEDI-551 4 mg/kg + Bendamustine · Cochran-Mantel-Haenszel · p = 0.3130
SecondaryTime to Response

Time to response was evaluated using the Kaplan-Meier method.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Median · Months
Time to Response
MonthsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Time to Response2.1 (1.9 to 2.6)1.9 (1.7 to 2.9)2.1 (1.9 to 3.5)
SecondaryTime to Disease Progression (TTP)

TTP was defined as the time from onset of treatment with study drug until first evidence/diagnosis of progressive disease or - in the absence of any diagnosis of progressive disease - until the participant´s death.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Median · Months
Time to Disease Progression (TTP)
MonthsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Time to Disease Progression (TTP)15.4 (12.0 to 27.2)15.0 (5.8 to 23.3)16.1 (12.5 to 24.0)
Statistical analysis
  • Rituximab + Bendamustine vs MEDI-551 4 mg/kg + Bendamustine · Log Rank · p = 0.9527
SecondaryProgression Free Survival (PFS)

PFS was measured from the start of treatment with study drug until the first documentation of disease progression or death due to any cause, whichever occurred first. Kaplan-Meier method was used for evaluation.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Progression Free Survival (PFS)14.8 (11.4 to 23.5)15.0 (5.8 to 22.1)16.1 (12.5 to 21.6)
SecondaryOverall Survival (OS)

OS was determined as the time from the start of treatment with study drug until death due to any cause. For participants who were alive at the end of the study or lost to follow-up, OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Number · Months
Overall Survival (OS)
MonthsRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (23.9 to NA)
SecondaryNumber of Participants Who Developed Detectable Anti-drug Antibodies (ADA)

A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.

Time frame:
From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Reported as:
Number · Participants
Number of Participants Who Developed Detectable Anti-drug Antibodies (ADA)
ParticipantsMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Number of Participants Who Developed Detectable Anti-drug Antibodies (ADA)48
SecondaryTerminal Half Life (t1/2) of MEDI-551

Terminal phase elimination half-life (T1/2) was the time required for half of the drug to be eliminated from the serum.

Time frame:
Pre-infusion and 1 hour post infusion on Days 2 and 8, Days 15 and 22 of cycle 1
Reported as:
Mean · Day
Terminal Half Life (t1/2) of MEDI-551
DayMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Terminal Half Life (t1/2) of MEDI-55117.2 ± 9.5622.0 ± 14.4

Adverse events

Collected over From start of study drug administration until 90 days after the last dose of study drug. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Bendamustine—19/60 (31.7%)58/60 (96.7%)
MEDI-551 2 mg/kg + Bendamustine—16/33 (48.5%)31/33 (93.9%)
MEDI-551 4 mg/kg + Bendamustine—19/57 (33.3%)54/57 (94.7%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Infusion related reactionInjury, poisoning and procedural complications1/605/335/57
PneumoniaInfections and infestations1/604/331/57
Febrile neutropeniaBlood and lymphatic system disorders6/600/332/57
SepsisInfections and infestations3/601/330/57
VomitingGastrointestinal disorders2/600/330/57
Abdominal lymphadenopathyBlood and lymphatic system disorders0/601/330/57
LymphadenopathyBlood and lymphatic system disorders0/601/331/57
ThrombocytopeniaBlood and lymphatic system disorders0/601/331/57
Anaphylactic reactionImmune system disorders0/601/331/57
BronchitisInfections and infestations1/601/331/57
Most frequent other events
Showing 10 of 109
Most frequent other events
EventRituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + Bendamustine
Infusion related reactionInjury, poisoning and procedural complications14/6021/3337/57
NauseaGastrointestinal disorders29/6013/3329/57
NeutropeniaBlood and lymphatic system disorders28/6010/3319/57
FatigueGeneral disorders18/6014/3320/57
ConstipationGastrointestinal disorders20/609/3310/57
AstheniaGeneral disorders20/604/337/57
PyrexiaGeneral disorders20/6011/3314/57
CoughRespiratory, thoracic and mediastinal disorders11/605/3319/57
AnaemiaBlood and lymphatic system disorders18/607/339/57
DiarrhoeaGastrointestinal disorders13/605/3311/57

Baseline characteristics

Intent-to-treat (ITT) Population includes all participants who were randomized into the study.

Age, Continuous
Age, Continuous(YEARS)Rituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + BendamustineTOTAL
Mean63.4 ± 8.865.1 ± 8.766.3 ± 8.965.1 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + BendamustineMEDI-551 2 mg/kg + BendamustineMEDI-551 4 mg/kg + BendamustineTOTAL
Female16141848
Male462243111
08

Study locations

54 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Burbank, California, United States
  • Research Site
    La Jolla, California, United States
  • Research Site
    Palm Springs, California, United States
  • Research Site
    Skokie, Illinois, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Fargo, North Dakota, United States
  • Research Site
    Dayton, Ohio, United States
  • Research Site
    Newark, Ohio, United States
  • Research Site
    Watertown, South Dakota, United States
  • Research Site
    Lubbock, Texas, United States
  • Research Site
    Morgantown, West Virginia, United States
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Arlon, Belgium
  • Research Site
    Kortrijk, Belgium
  • Research Site
    Mons, Belgium
  • Research Site
    Wilrijk, Belgium
  • Research Site
    Yvoir, Belgium
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Greenfield Park, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Amiens, France
  • Research Site
    Bayonne, France
  • Research Site
    Bordeaux, France
  • Research Site
    Le Mans, France
  • Research Site
    Libourne Cedex, France
  • Research Site
    Marseille, France
  • Research Site
    Nimes, France
  • Research Site
    Dortmund, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Muenchen, Germany
  • Research Site
    Wuerzburg, Germany
  • Research Site
    Haifa, Israel
  • Research Site
    Ramat Gan, Israel
  • Research Site
    Bari, Italy
  • Research Site
    Lecce, Italy
  • Research Site
    Meldola, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Modena, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Orbassano, Italy
  • Research Site
    Palermo, Italy
  • Research Site
    Pisa, Italy
  • Research Site
    Ravenna, Italy
  • Research Site
    Rimini, Italy
  • Research Site
    Roma, Italy
  • Research Site
    San Giovanni Rotondo, Italy
  • Research Site
    Torino, Italy
  • Research Site
    Udine, Italy
  • Research Site
    Gdynia, Poland
  • Research Site
    Warszawa, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2011
First posted
Nov 6, 2011
Start
Feb 7, 2012
Primary completionActual
Jan 8, 2016
CompletionActual
Jan 8, 2016
Results first posted
May 31, 2017
Last update
May 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01466153
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Nov 6, 2011
Start date
Feb 7, 2012
Primary completion
Jan 8, 2016
Completion
Jan 8, 2016
Results posted
May 31, 2017
Last update
May 31, 2017

Study contacts

MedImmune
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion